Accessibility Menu
Novavax logo

Novavax

(NASDAQ) NVAX

Current Price$8.88
Market Cap$1.46B
Since IPO (1995)-89%
5 Year-95%
1 Year+37%
1 Month-20%

Novavax Financials at a Glance

Market Cap

$1.46B

Revenue (TTM)

$596.34M

Net Income (TTM)

-$87.84M

EPS (TTM)

-$0.60

P/E Ratio

-14.86

Dividend

$0.00

Beta (Volatility)

1.80 (High)

Price

$8.88

Volume

8,409,598

Open

$8.53

Previous Close

$8.88

Daily Range

$8.53 - $8.94

52-Week Range

$6.20 - $11.97

Estimated Earnings Date

Aug 5, 2026

NVAX: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novavax

Industry

Biotechnology

Employees

749

CEO

John C.s Jacobs, MBA

Headquarters

Gaithersburg, MD 20878, US

NVAX Financials

Key Financial Metrics (TTM)

Gross Margin

84.64%

Operating Margin

-11.19%

Net Income Margin

-14.73%

Return on Equity

89.73%

Return on Capital

465.29%

Return on Assets

-8.42%

Earnings Yield

-6.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.46B

Shares Outstanding

164.44M

Volume

8.41M

Avg. Volume

4.74M

Financials (TTM)

Gross Profit

$504.72M

Operating Income

-$66.76M

EBITDA

-$42.13M

Operating Cash Flow

-$91.56M

Capital Expenditure

-$5.61M

Free Cash Flow

-$97.17M

Cash & ST Invst.

$790.33M

Total Debt

$295.06M

Novavax Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$139.51M

-79.1%

Gross Profit

$108.82M

-83.3%

Gross Margin

78.00%

N/A

Market Cap

$1.46B

N/A

Market Cap/Employee

$1.53M

N/A

Employees

952

N/A

Net Income

-$9.49M

-101.8%

EBITDA

-$543.00K

-100.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$790.33M

+8.0%

Total Debt

$295.06M

+29.0%

Accounts Receivable

$23.31M

-47.6%

Inventory

$11.46M

+11.6%

Long Term Debt

$292.95M

+31.3%

Short Term Debt

$2.11M

-61.4%

Return on Assets

-8.42%

N/A

Return on Invested Capital

-9.53%

N/A

Free Cash Flow

-$33.69M

+82.0%

Operating Cash Flow

-$32.42M

+82.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NKTRNektar Therapeutics
$63.65+2.61%
PGENPrecigen, Inc.
$5.86+6.16%
ZBIOZenas BioPharma, Inc.
$25.87+4.86%
WVEWave Life Sciences Ltd.
$5.83+1.39%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.87+0.02%
SPCXSpace Exploration Technologies
$153.23+0.00%
ONDSOndas
$7.83+0.02%
KEELKeel Infrastructure
$6.03+0.03%

Questions About NVAX

What is the current price of Novavax?

Novavax is trading at $8.88 per share.

What is the 52-week range for Novavax?

Over the past 52 weeks, Novavax has traded between $6.20 and $11.97.

How much debt does Novavax have?

As of the most recent reporting period, Novavax reported total debt of $295.06M.

How much cash does Novavax have on hand?

Novavax reported $228.36M in cash and cash equivalents in its most recent financial results.

What is Novavax’s dividend yield?

Novavax does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.